The $16M USD round was led by Celesta Capital, with participation from Tenacity Ventures, Cedars Sinai; OneCell to continue transforming the future of precision oncology with U.S. market entry

CUPERTINO, Calif. and MUMBAI, India, Nov. 21, 2024 /PRNewswire/ -- OneCell Diagnostics, a genomics-based precision oncology company, announced today that it has raised $16M in an oversubscribed Series A funding round led by Celesta Capital, with participation from Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Ventures. The funding will be used to advance its vision of democratizing precision oncology through cancer diagnostic testing that is more accessible, actionable, and affordable. Celesta Capital Founding Managing Partner Michael Marks and Nobel Laureate and Celesta Capital Senior Advisor Dr. James Rothman will join the OneCell board of directors.

We want to hear from you For general questions or concerns, email [email protected]